1. Home /
  2. Drug Approvals

Drug Approvals

As Biogen Surges on Alzheimer Trial Results, Here's How to Play It

BIIB shares have jumped around 50% in early trading activity Wednesday.

Point of No Return, Punishing Mistakes, Gnarly Bond Spread, 2 Possible Catalysts

Plus, we take looks at Eli Lilly and Raytheon Technologies after positive news developments for both companies.

Nuvalent Has Made a Base Pattern on the Charts

This biopharmaceutical firm shows promise.

Here's My Prescription for Bristol-Myers Squibb

I'm bullish long term, but for now, can BMY generate follow-through buying?

Regeneron Soars But This Biotech ETF Is the Better Way to Get Exposure

Let's check the charts and indicators of the IBB.

A Technical Strategy to 'Buy' Agios Pharmaceuticals

Here's what aggressive traders could do now.

Lilly Disappoints All Around But Here's When I Would Invest

This stock is in a technical state of weakness and add that to the eroding fundamentals.

Allogene Therapeutics' Charts Suggests a Rally Ahead

Here's how traders can play the stock.

Incyte's Setup Should Inspire Bullish Traders

Buyers of the biopharmaceutical's stock are being more aggressive than sellers.

Cytokinetics Is Showing Its Muscles on the Charts

In light of the stock market's weakness, CYTK has shown impressive strength.